A study, published in Mayo Clinic Proceedings, demonstrates that Cologuard (mt-sDNA) is the most cost-effective colorectal cancer screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test, for a wide range of adherence scenarios.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
